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ABSTRACT: Cost data are frequently collected from several locations and tend to
be non negative and skewed. Generalised linear multilevel models provide a means
of dealing with each of these issues. This paper compares several statistical models
within this class using data drawn from an observational study of 3,000 patients
treated for heart attack in 15 UK NHS hospitals. A number of alternative link
functions and covariates were considered. We demonstrate that whilst it is important
to take account of clustering in the data, the precise manner in which this is done is
equally important. Models which allow for correlation between the random e¤ects
components and heteroskedasticity across all hospitals performed best in terms of
model t and made substantial di¤erences to cost estimates.
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1 Introduction
It is a requirement of cost e¤ectiveness analysis that estimates are based on mean
costs and benets since this is most relevant to informing decision makers of the
true expected costs and benets of adopting a particular intervention across a pop-
ulation. Typically however, cost data are non negative and highly skewed. It may
therefore be inappropriate to employ standard methods of analysis which rely on the
assumption of conditional normality in seeking to estimate mean costs conditional
on treatment or other characteristics. There are two broad approaches that can
be used to attempt to overcome the challenge of skewness. Transformations, such
as taking the logarithm of cost, which produce a more normal distribution can be
undertaken, with standard methods then conducted on the transformed data. This
approach raises additional di¢ culties however since it is not a straightforward task
to back transform the estimates to the original cost scale without introducing bias
(Duan (1983)). More recently, approaches using Generalized Linear Models (GLMs)
have been conducted in the health economics literature (see for example Blough and
Ramsey (2000) Glick (2007)). The GLM approach is more attractive since costs
can be analysed on their original scale directly. This is achieved by allowing for a
variety of distributions, not necessarily normal, to be specied for costs. These two
approaches have been compared by Manning and Mullahy (2001).
An additional complication is that many studies are conducted in multiple set-
tings. This is particularly true of randomized controlled trials which are often mul-
ticentre giving rise to natural clusters within the data. Such clustering ought not
be ignored. Observations from the same cluster will not be independent and failure
to incorporate this may lead to misleading results. Whilst standard GLM models
assume that all the observations in the sample are independent, multilevel mod-
elling techniques (Goldstein (2005)), also referred to as hierarchical or mixed e¤ects
models, can be used to account for clustering in the data. Multilevel models are
constructed by allowing one or more of the model parameters to vary across centres
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and there is a small but growing literature on their use in health economics. Most of
these applications have used a normal distribution to model the dependent variable
(Or et al. (2004), Willan et al. (2005), Manca et al. (2005), Manca et al. (2007)) or
its logarithm (Carey (2000)) but there are also some applications where GLM and
multilevel models (GLMMs) have been combined to simultaneously account for both
non normal distributions and clustering in the data (Burgess et al. (2000), Grieve
et al. (2005), Gauthier et al. (2009), Thompson et al. (2006), Grieve et al (2009),
Willan and Kowgier (2008)). Liu et al. (2009) and Cooper et al. (2007) demon-
strate how implementation of GLMMs as part of a two part (also known as hurdle)
modelling framework may be valuable in situations where there are a signicant
proportion of zero cost observations. The rst part of the model is used to predict
whether a patient incurs a positive cost of not, with a GLMM then tted to the
second part for patients that do.
Few of these GLMM applications allow for heterogeneity in more than one model
parameter. In most cases, where the primary interest is in the e¤ect of di¤erent
treatments on costs, a single random e¤ect is used either for the intercept or the
active treatment covariate but not both. An exception is Thompson et al. (2006)
who examined the costs of stroke patients in 13 international centres and the impact
of incontinence, a marker of stroke severity, on those estimates. Heterogeneity is
reected in both parameters although the fact that these are treated as independent
may itself be seen as a limitation. In many situations, it may be overly simplistic
to have such limitations on the random structure of the model. For example, the
units which give rise to the multilevel structure of the data such as countries or
hospitals may well be expected to di¤er in terms of the costs of both control and
active treatment. There are also many situations in which our interest extends to
multiple treatments and their associated costs. Furthermore it is inevitable that
these random parameters are themselves correlated and it would be appropriate for
any cost model to reect this in order to avoid inappropriate estimates.
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This paper illustrates the application of such models. We aim to develop the
GLMM framework for the analysis of cost data further by allowing for heterogene-
ity in multiple parameters whilst also incorporating a full correlation matrix in the
random component of the model. We compare these models with standard GLMs
and a GLMM without such correlations. These issues are demonstrated using cost
data for UK NHS hospital heart attack patients between April 2005 and March 2006
treated either by thrombolytic (clot-busting) drugs or primary percutaneous coro-
nary intervention (primary angioplasty or PPCI). We therefore have three random
treatment parameters unlike many previous applications based on two arm RCTs.
Analyses are performed using maximum likelihood estimation methods using STATA
software, in contrast to almost all other applications we are aware of that have used
Monte Carlo Markov Chain (MCMC) simulation methods.
Section 2 of the paper provides brief details of the study which provided the
patient level data used in the analyses. Section 3 presents the GLM and GLMM
models. Results for all models are provided in Section 4 whilst Section 5 discusses
those results and concludes.
2 Data
Current standard treatment for acute myocardial infarction (heart attack) centres
on rapid, clot-busting (thrombolytic) drug treatment. However, evidence from a
number of trials dating from the early 1990s suggests that primary angioplasty
may be more benecial in terms of mortality, reinfarction and stroke (Asseburg
et al. (2007)). It has been estimated that primary angioplasty represents a cost
e¤ective treatment in the UK NHS setting provided the additional time delay to
treatment does not exceed approximately one hour compared to thrombolysis (Bravo
Vergel et al. (2007)). However, these estimates were based on several assumptions
about likely resource use. Given the organisational challenges of providing a 24
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hour angioplasty service, the UK NHS set up a pilot scheme, the National Infarct
Angioplasty Project (NIAP), in order to investigate the feasibility of a national roll-
out of a comprehensive angioplasty service. One of the aims of the pilot was to
gather resource use data to allow real-life estimates of cost to be made which in turn
could be used to make updated estimates of cost-e¤ectiveness (Goodacre (2008),
Wailoo et al. (2009)).
Ten hospitals providing primary angioplasty became NIAP pilot sites and col-
lected detailed data on the initial treatment episode and follow up information to one
year for all ST - segment elevation myocardial infarction (STEMI) patients admitted
between 1st April 2005 and 31st March 2006. These hospitals varied in terms of the
times of day and the days of the week primary angioplasty was provided (not all
o¤ered 24/7 provision during the study period) and whether they had arrangements
with local hospitals unable to provide angioplasty for patients to be transferred for
primary angioplasty. These hospitals provided information on 2083 patients. As
part of NIAP, one hospital that did not provide primary angioplasty also collected
data for the study period. We supplemented this control site information by ob-
taining equivalent data for the same time period from four other hospitals who did
not provide primary angioplasty for their STEMI patients. A total of 919 control
patients were included.
Data were collected on treatment received, drugs administered, consumables
including the number, type and make of stent, tests, length of stay, sta¢ ng of
the catheter laboratories and ambulance journeys. These were costed at 2006/7 £
sterling values.
These data come from an observational study, not a randomised controlled trial.
Whilst the study o¤ers distinct advantages over RCTs because of the real life setting,
di¤erences between the patients at di¤erent hospitals and receiving di¤erent treat-
ments is not considered in the design and is therefore a genuine concern that may
be less relevant to trials. Therefore, data on a wide range of patient characteristics
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were included as potential covariates to the cost analysis. Table 1 provides details of
the main characteristics of the sample by NIAP and control hospitals. Statistically
signicant di¤erences can be seen in several dimensions. The patients treated in
NIAP hospitals were slightly younger (64 vs 66yrs), more likely to be male (71% vs
67%), more ethnically diverse with 81% caucasian compared to 98% in the control
hospitals, had a greater prevalence of previous heart disease such as angina (22%
vs 16%), previous percutaneous coronary intervention (PCI)(9% vs 3%) or previous
coronary artery bypass graft (CABG)(4% vs 1%). There was also evidence that the
NIAP treated patients had a greater prevalence of other comorbidities.
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Table 1: Characteristics of patients
NIAP sites Control sites
(n=2083) (n=919)
mean std err mean std err
Mean age in years 63.5*** 0.31 66.1*** 0.44
MI severity Mean peak troponin 32.3*** 3.8 19.9*** 0.71
% n % n
Ethnic group Caucasian 80.5*** 1407 98.0*** 624
Black 2.9 50 0.3 2
Asian 11 192 1.6 10
Oriental 0.5 9 0.2 1
Previous CHD AMI 15.9 326 15 136
Angina 21.8*** 441 15.9*** 76
Previous PCI 8.6*** 176 2.6*** 23
Previous CABG 3.8*** 78 1.3*** 10
Comorbidities Hypertension 45.9*** 931 39.3*** 327
Hypercholesterolaemia 40.3 789 43.3 343
Peripheral vascular disease 4.3*** 87 2.0*** 12
Cerebrovascular disease 6.4 129 5.1 44
Asthma or COPD 11.8 238 11.4 97
Chronic renal failure 2.5 50 2.1 19
Diabetes 16.6*** 339 11.17*** 101
Left Ventricular Good 55.7 547 58.3 151
Ejection Function Moderate 33.3 327 34.36 89
Poor 11.1 109 7.34 19
Male 71.1** 1479 66.5** 611
Notes: *** - sign icant at 1% level, ** - sign icant at 5% level, * - sign icant at 10% level.
AM I - Acute Myocard ia l In farction , CHD - Coronary Heart D isease, COPD - Chron ic Obstructive Pulmonary D isease
Figure 1 displays histograms to demonstrate the distribution of the data for the
individual hospitals and overall. It can be seen that there are substantial deviations
from normality in the cost distributions both at the aggregate and individual hospital
levels. In addition, the degree of skewness and kurtosis di¤ers substantially by
hospital. For example, the distribution for hospital 3 is leptokurtic with data in
the right tail extending to around £ 15,000. The distribution for hospital 5 is more
platykurtic but still contains data in the tail extending to the same range as hospital
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3. The right skew is less pronounced for hospitals 6 and 13, with few observations
exceeding £ 10,000. The mean cost of the treatment episode ranges from £ 2,408 to
£ 5,329 across the hospitals.
It is therefore clear that the use of a normal distribution to model this cost data is
unlikely to be appropriate but, in addition, the data may be more fully represented
by approaches which permit the shape of the chosen distribution to vary across
hospitals. No individual patient had a zero cost.Two part models are therefore not
required in this situation.
3 Model specication
The focus of the paper is to estimate the impact of "no treatment", thrombolysis
and PPCIon the cost of the initial treatment episode. We control for a number of
covariates at both the individual and the hospital level to try to isolate as much as
possible the e¤ect on costs of these three variables. The GLMs presented here use a
gamma distribution with an identity link. Other specications, including di¤erent
families and links, were also estimated but the gamma distribution with additive
e¤ects of the covariates on the mean was found to t the data better according to
both the Akaike Information Criterion (AIC) and the Bayesian Information Criterion
(BIC).
All multilevel models have been estimated using the program GLLAMM written
in STATA by Rabe-Hesketh et al. (2004). This program uses maximum likelihood es-
timation. The marginal log-likelihood is obtained by using adaptive Gauss-Hermite
quadrature to integrate out numerically the latent variables.
The estimation of four models is reported in the next section. These four models
are described below in order of complexity.
Model 1: Generalised Linear Model. This is the simplest model where costs are
modelled in a GLM framework. It ignores the multilevel structure of the data and
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is only estimated for comparison purposes. Let cij be the initial cost of treatment of
patient i (i = 1 to N) in hospital j (j = 1 to 15). Using a gamma distribution with
mean i and shape  and an identity link, the model for cij can then be written as:
cij~  (i; ) ; i =
3X
s=1
sxijs + 4dijxij1 + 5dijxij2 + 6tijxij3 +
X
k
kzijk
where xij1, xij2 and xij3 are dummy variables for "no treatment", thrombolysis
and PPCIrespectively, zijk represent di¤erent covariates (k = 1 to 8) to control
for di¤erences across individuals, dij is a dummy variable equal to one if patient
i went to a NIAP centre and tij is a dummy variable equal to one if the PPCI
was performed out of hours. In this set-up 4 and 5 represent a di¤erential e¤ect
on the initial cost of treatment between NIAP and control hospitals and 6 is the
di¤erential e¤ect of out of hours PPCI.
The model assumes that the e¤ects of "no treatment" (1), thrombolysis(2)
and PPCI(3) on costs are the same across all the hospitals in our sample. This
assumption is relaxed in the following four models.
Model 2: Generalised Linear Multilevel Model with independent random e¤ects and
level 1 clustering (heteroskedasticity). This model generalises Model 1 by taking into
account the multilevel structure of the data. Patients are grouped within hospitals
which di¤er in many organisational and geographical factors which are likely to have
a substantial bearing on overall cost. Costs within hospitals tend to vary less than
costs for patients chosen at random from di¤erent hospitals. Ignoring this structure
in the data may lead to making inappropriate inferences. The initial cost of the
treatment for patient i in hospital j is modelled using a gamma distribution as
before but now the coe¢ cients of "no treatment", thrombolysisand PPCIare
no longer the same across hospitals. It is assumed that these three coe¢ cients vary
randomly across hospitals, each one of them following its own normal distribution
with its own mean and variance. This model also allows the "shape" of the gamma
9
distribution to di¤er across NIAP (1) and control hospitals (2). This extended
model can be written as:
cij~ 
 
ij; r

; ij =
3X
s=1
sjxijs +
X
k
kzijk; r = 1; 2:
0BBBB@
1j
2j
3j
1CCCCA ~N
0BBBB@
0BBBB@
1 + 4dij
2 + 5dij
3 + 6tij
1CCCCA ;
0BBBB@
21 0 0
0 22 0
0 0 23
1CCCCA
1CCCCA
It is important to note that this model recognises explicitly the fact that dij and
tij relate to e¤ects at the hospital level and not at the individual level.
The parameters to be estimated in this model can be divided into those corre-
sponding to the xed component of the model (1 to 6 and 1 to 8) and those
corresponding to the random component (21, 
2
2 and 
2
3). This can be easily seen
by writing the random coe¢ cients as:
1j = 1 + 4dij + u1j u1j~N
 
0; 21

2j = 2 + 5dij + u2j u2j~N
 
0; 22

3j = 3 + 6tij + u3j u3j~N
 
0; 23

and substituting these equations into the mean of the gamma distribution
ij =
3X
s=1
sjxijs + 4dijxij1 + 5dijxij2 + 6tijxij3 +
X
k
kzijk +
3X
s=1
usjxijs
Model 3: Generalised Linear Multilevel Model with correlated random e¤ects and
level 1 clustering. This model relaxes the assumption of model 2 that the ran-
dom e¤ects are uncorrelated. This assumption might be an appropriate assumption
to make in some cases but may be considered particularly strong in this example.
Within the same hospital, the costs of treating patients by angioplasty or thrombol-
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ysis and the costs of no treatment would each be likely to be correlated. Therefore,
in model 3 the three random e¤ects are assumed to follow a joint normal distribution
with means identical to model 2 but allowing for non-zero covariances.
cij~ 
 
ij; r

; ij =
3X
s=1
sjxijs +
X
k
kzijk; r = 1; 2
0BBBB@
1j
2j
3j
1CCCCA ~N
0BBBB@
0BBBB@
1 + 4dij
2 + 5dij
3 + 6tij
1CCCCA ;
0BBBB@
21 12 13
12 
2
2 23
13 23 
2
3
1CCCCA
1CCCCA
Model 4: Generalised Linear Multilevel model with correlated random e¤ects and
level 1 heteroskedasticity across all hospitals. This nal model allows for di¤erent
shape parameters of the gamma distribution for every hospital in the sample. The
previous GLMM models allow only two gamma shape parameters, one which is
identical for all NIAP hospitals and one which is identical for all control hospitals.
Consideration of the cost distributions (see Figure 1) illustrates that this may not
be an appropriate simplication. Model 4 can be written as:
cij~ 
 
ij; r

; ij =
3X
s=1
sjxijs +
X
k
kzijk; r = 1; 2; : : : ; 15
0BBBB@
1j
2j
3j
1CCCCA ~N
0BBBB@
0BBBB@
1 + 4dij
2 + 5dij
3 + 6tij
1CCCCA ;
0BBBB@
21 12 13
12 
2
2 23
13 23 
2
3
1CCCCA
1CCCCA
3.1 Hypothesis testing and model comparisons.
Parameter estimates and standard errors for the xed parts of the multilevel models
(1 to 6 and 1 to 8) can be used to make inferences about signicance using
standard approaches such as t-tests. However, in general, these usual tests are not
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adequate for the random parts of the models since the true variance value might
be on the boundary of the parameter space, making inferences unreliable. In these
cases, it is better to base inferences on the likelihood ratio statistic. To test a null
hypothesis H0 against an alternative hypothesis HA, the following likelihood ratio
statistic is used:
LR =  2 ln

L0
LA

where L0 and LA are the likelihoods for the null and alternative hypothesis re-
spectively. Under the usual regularity conditions, this statistic has a chi squared
distribution with degrees of freedom equal to the di¤erence in the number of es-
timated parameters between the null and the alternative hypotheses. However, in
cases where the null hypothesis involves parameters that are on the boundary of the
parameter space the asymptotic distribution of the likelihood ratio statistic needs
to be derived. In this situation, the likelihood ratio test is too conservative in the
sense that the true p-value of the test will be smaller, as has been shown by Self and
Liang (1987) , Skrondal (2004) and Verbeke and Molenberghs (2003). Therefore,
caution should be exercised where the p-value indicates that there is no evidence to
reject the null whereas one can be condent in the converse case.
4 Results
Initially, we included a broad range of covariates in a GLM, covering treatment type
and location, other treatments given within the episode, patient demographics and
comorbidities. Variables were only deleted from the model in cases where they were
grossly insignicant with t-values well below one although treatment and location
variables were always maintained. A quadratic e¤ect of age on total cost was found
to perform better either than using age on its own or the logarithm of age. Data on
previous Acute Myocardial Infarction (AMI), angina, PCI and CABG had a large
number of missing values. Two di¤erent specications were considered: one with
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all four dummy variables and another where they were combined in one dummy
variable with a value of one if patients had any of previous AMI, angina, PCI and
CABG. The latter model had a better t and was therefore retained (Model 1). All
other models are developed from Model 1 with results shown in Table 2.
Model 1 is the standard GLM with no account taken of the multilevel nature of
the data. It can be seen from Table 2 that the cost of thrombolysis (£ 2,639) is only
slightly higher than the cost of no treatment (£ 2,540) in control hospitals. Primary
angioplasty is substantially more costly at £ 4,310. There are additional costs of
£ 665 and £ 263 for thrombolysis which occurs in a NIAP hospital and for primary
angioplasty that occurs out of standard working hours, respectively. Treatment cost
increases with patient age. We also nd substantial and signicant positive e¤ects
on costs where patients have pre-existing vascular disease or other comorbidities.
Where other coronary procedures are undertaken within the admission, costs are
higher with CABG adding £ 4,950 to the total cost.
Some of the restrictions embedded in Model 1 are relaxed cumulatively in Models
2, 3, and the preferred model, Model 41. The model t as assessed by both AIC
and BIC improves as these restrictions are relaxed. Similarly, using the conservative
p-values, the likelihood ratio test rejects models 1, 2 and 3 in favour of model 4 with
the following test statistics respectively (conservative p-values in square brackets),
1866.90[0.00], 173.40[0.00] and 162.04[0.00].
It is noticeable that as the random e¤ects are incorporated into the models, the
standard errors relating to the treatment-type covariates increase substantially. This
is as expected since clustering in the data, which was masked in Model 1, reduces
the amount of information that can be gained from each observation. It is also
worth noting that the variances of the random e¤ects are very large reecting the
variability across hospitals and that the correlations between the random e¤ects are
signicant. Using the results of Model 4, the interval in which 95% of hospitals are
1Initially we used 24 integration points to calculate the integrals and increased it to 28 to check
the stability of the estimated parameters.
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expected to fall is £ 695 to £ 4,819 for the no treatment intercept, £ 1,512 to £ 4,303
for the thrombolysis intercept and £ 3,697 to £ 5,145 for the primary angioplasty
intercept.
The relaxation of the restriction embedded in Model 1, that there is a common
scale to the gamma distribution across all hospitals, is undertaken in two ways.
Models 2 and 3 allow separate scale parameters for NIAP versus Control hospitals,
whilst in Model 4 the scale parameter is allowed to di¤er across all hospitals. The
improvement in the t gained by Model 4 indicates that this greater degree of
separation is preferable and that the distinction between NIAP and control sites is
not the cause of across hospital di¤erences in the scale.
Compared to Model 1, the expected episode cost for all treatments is much higher
but also the di¤erences between treatments vary. For example, the di¤erence in cost
between thrombolysis in a NIAP centre compared to primary angioplasty falls from
over £ 1,000 in Model 1 to £ 760 in Model 4. We also nd that the cost of primary
angioplasty performed out of standard working hours is approximately £ 100 higher
in Model 4. The impact of comorbidities also varies substantially between models 1
and 4, with substantially lower costs assigned to the presence of vascular disease or
other comorbidities in the latter model.
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Table 2: Parameter estimates for Models 1 to 4
Model 1 Model 2 Model 3 Model 4
No treatment (control) 2540:16
(178:35)
2668:11
(441:80)
2788:46
(456:98)
2757:31
(309:75)
Thrombolysis (control) 2638:52
(96:09)
2934:54
(294:47)
2947:77
(304:25)
2907:65
(297:83)
PPCI (NIAP) 4310:00
(133:29)
4455:94
(171:42)
4479:11
(168:41)
4421:02
(155:99)
No treatment (NIAP)  63:27
(189:10)
 60:12
(523:22)
 264:85
(532:71)
Thrombolysis (NIAP) 664:94
(162:36)
501:93
(387:11)
600:45
(396:76)
754:31
(365:95)
Out of hours PPCI 263:45
(156:16)
262:01
(136:95)
213:31
(135:32)
362:80
(118:50)
(age-64)/10 390:79
(37:74)
352:38
(34:30)
350:29
(34:13)
332:33
(31:85)
((age-64)/10)2 63:56
(20:70)
62:97
(15:07)
61:06
(15:14)
65:96
(14:57)
Previous coronary heart disease 130:73
(117:64)
189:71
(100:71)
186:63
(100:79)
217:53
(97:04)
Vascular/cerebrovascular disease 1026:15
(213:38)
972:49
(181:80)
958:20
(181:09)
842:84
(166:88)
Other comorbidities 467:84
(89:30)
251:16
(80:87)
248:85
(81:02)
198:22
(75:30)
Dead at discharge  752:43
(170:14)
 716:04
(170:32)
 694:73
(168:62)
 704:52
(176:45)
Non primary PCI in this admission 201:50
(161:50)
267:55
(155:08)
233:57
(152:31)
287:88
(146:52)
CABG at this admission 4949:73
(1096:61)
4673:96
(905:94)
4648:99
(907:15)
4767:03
(877:15)
Scale parameter 0:34
(NA)
(1)
Scale parameter NIAP 0:23
(0:01)
0:23
(0:01)
Scale parameter Control 0:36
(0:01)
0:36
(0:01)
Random e¤ects
1 833:07
(203:88)
833:25
(202:01)
1052:04
(277:55)
2 607:75
(155:49)
630:40
(165:53)
711:84
(202:42)
3 393:59
(118:26)
384:99
(106:17)
369:46
(109:19)
12 0:49
(0:33)
0:67
(0:24)
13 0:87
(0:18)
0:57
(0:30)
23 0:00
(0:46)
 0:23
(0:40)
AIC 43825.15 43819.79 43681.76
BIC 43838.61 43835.37 43705.83
Standard errors are provided in brackets. For the random part of the models they shou ld b e interpreted w ith caution
(1) Separate scale param eters for a ll 15 hosp ita ls, range = 0.09 to 0.39
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5 Discussion
In this paper, we compare di¤erent models which attempt to deal with the challenges
posed by data that is both non-normally distributed and clustered. We demonstrate
how a GLM can be developed to incorporate random e¤ects and to allow for di¤er-
ences in the scale according to cluster using cost data from an observational study
of UK NHS heart attack patients.
Health care is dominated by studies that generate data that is hierarchical in
nature. To date, most applications of multilevel models in health economics have
focussed on clinical trials (Willan et al. (2005), Grieve et al. (2005), Manca et
al. (2005)). This is natural since, for reasons of practicality and to demonstrate
generalisability, trials are frequently conducted at multiple centres, sometimes in
multiple countries. Thompson et al. (2006) recognise that data generated by obser-
vational studies often also include clustering.
We demonstrate that accounting for clustering in the data through multilevel
models is important but furthermore, consideration of alternative specications of
the random e¤ects components of the statistical model is required as well as the
specication of the xed e¤ects. In our example, we nd that the preferred model
is one which allows for separate random e¤ects for treatment type by hospital,
correlations between those random e¤ects, and separate scale parameters for each
hospital. Model selection is based on the AIC/BIC and Likelihood Ratio tests.
Substantial di¤erences in cost estimates are apparent between the various models.
Failure to appropriately account for both skewness and clustering in the data
may result in biased estimates of treatment cost and its variance. In our example,
there are substantial di¤erences in the cost estimates between the GLM model that
does not account for clustering at all and the multilevel models that do. But in
addition, there are substantial di¤erences between the various multilevel models.
In particular, the di¤erences in the estimated costs of thrombolysis versus angio-
plasty, and the cost of angioplasty performed in or out of hours, could be su¢ cient
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to translate into substantial di¤erences in cost e¤ectiveness estimates and subse-
quently decision making. Indeed, our analysis of treatment costs for heart attack
are primarily intended to inform a cost e¤ectiveness model comparing primary an-
gioplasty with thrombolysis where much of the clinical e¤ectiveness data is rightly
drawn from trials (Wailoo et al. (2009)). However, observational datasets of this
type may often be more appropriate for estimating real world resource use com-
pared to the articial environments of clinical trials. The use of statistical models
that include a variety of covariates to control for di¤erences between patient groups
is more likely to be a requirement for analysis of observational datasets given the
non randomised nature of the patient samples. We considered a large number of
regressors that reect patient and hospital characteristics as well as the treatments
themselves.
Most studies to date that have used multilevel models in analysis of cost or
cost e¤ectiveness data have maintained the assumption of normality (Carey (2000),
Burgess et al. (2000), Willan et al. (2005)). Our study demonstrates, in common
with both Thompson et al. (2006) and Manca et al. (2005), that both skewness and
clustering can be incorporated simultaneously. In addition, most previous studies
have not considered correlations between the random e¤ects. Manca et al. (2005)
and Manca et al. (2007) provide examples that did include such terms based on
cost e¤ectiveness data in multicentre trials. Manca et al. (2005) only uses a single
treatment covariate whereas our observational dataset required the consideration of a
large number of potential covariates, 14 of which are retained in the preferred model.
Our study complements and extends this work by demonstrating the improvement
in model t that can be obtained between alternative specications both of the
random e¤ects and the scale parameter.
Finally, one minor di¤erence is in the implementation of the statistical mod-
els. Almost all published applications of multilevel models have been perfomed
in a Bayesian framework, using Monte Carlo Markov Chain (MCMC) simulation
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methods (Manca et al. (2007), Thompson et al. (2006), Cooper et al. (2007)) which
is sometimes seen as a more straightforward means of implementing non standard
models. The use of quadrature techniques for estimation have been shown to o¤er a
convenient alternative in standard statistical packages such as the STATA module
(GLAMM) in this example and in SAS (Liu et al. (2009)).
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